SCHEMBL5714563

SCHEMBL5714563

CC1(C)CC(=O)N(CCc2ccc(OC(=O)N3CCN(c4ccc(Cl)cn4)CC3)nc2)C(=O)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ME2 P23368 2/20 0.43
ME1 P48163 2/20 0.43
ME3 Q16798 2/20 0.43
TACR3 P29371 7/20 0.42
AOC3 Q16853 1/20 0.40
HTR1A P08908 2/20 0.39
DRD2 P14416 2/20 0.39
DRD4 P21917 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
DRD3 P35462 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
PANK3 Q9H999 1/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714493 0.91 PANK3 (0.45) ME2ME1ME3TACR3HTR1A
SCHEMBL5715059 0.90 AOC3 (0.40) ME2ME1ME3TACR3AOC3
SCHEMBL5714605 0.90 AOC3 (0.42) ME2ME1ME3AOC3HTR1A
SCHEMBL5715118 0.90 ME2 (0.43) ME2ME1ME3TACR3AOC3
SCHEMBL5715436 0.89 HRH3 (0.41) ME2ME1ME3AOC3HTR1A
SCHEMBL5714782 0.87 SMN1; SMN2 (0.53) TACR3
SCHEMBL5715599 0.87 ALDH1A1 (0.45) HTR1ADRD2HTR2AHTR2CHTR7
SCHEMBL5715321 0.84 HTR1A (0.39) AOC3HTR1ADRD2HTR2AHTR2C
SCHEMBL5715028 0.83 TACR3 (0.43) ME2ME1ME3TACR3DRD2
SCHEMBL5715145 0.82 PANK3 (0.42) ME2ME1ME3AOC3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ME2 854/4885ME1 2914/4885ME3 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.